Navigation Links
MannKind Corporation to Host Webcast Analyst Day September 16, 2008
Date:9/11/2008

Company To Review Data from First Pivotal Phase 3 Clinical Trial

VALENCIA, Calif., Sept. 11 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today announced that it will host an analyst day for the investment community to review clinical results from Phase 3 and other clinical trials of the company's Technosphere(R) Insulin System. The meeting will take place on Tuesday, September 16, 2008 from 9 a.m. to 11 a.m. Eastern Time in New York City. To access the live audio broadcast or the subsequent archived recording, please visit the MannKind Corporation web site at http://www.mannkindcorp.com.

Mr. Al Mann and other members of MannKind's management will review the Phase 3 data, and the meeting will also feature John ("Jack") E. Gerich, M.D., a world renowned diabetologist and expert in the physiology of diabetes and glucose metabolism. Dr. Gerich is professor of medicine and physiology and director of the clinical research center at the University of Rochester School of Medicine.

About the Technosphere(R) Insulin System

MannKind's investigational inhaled insulin product consists of its proprietary Technosphere(R) particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using MannKind's proprietary MedTone inhaler. A long sought-after goal in the treatment of diabetes has been to produce a profile of insulin levels in the bloodstream that closely mimics the normal human physiologic insulin response. In clinical studies to date, the Technosphere(R) Insulin System has been consistently observed to produce peak insulin levels within 12-14 minutes of inhalation, which approximates
'/>"/>

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. MannKind Announces New $350 Million Credit Facility
2. MannKind to Present at Upcoming Conferences
3. MannKind Corporation Reports Third Quarter Financial Results
4. MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results
5. MannKind to Present at the Cowen and Company Healthcare Conference
6. The Leukemia & Lymphoma Society and MannKind Corporation Announce Collaborative Research Agreement
7. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
8. Brooke Franchise Corporation Announces Selected July Results
9. MedThink Communications Retained by NanoBio Corporation
10. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
11. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... TX (PRWEB) July 25, 2014 ... Outlook to 2020” provides company shares and distribution ... and global corporate-level profiles of the key market ... to the Laryngoscopes market wherever available. , The ... market forecast models. Rsearcher uses epidemiology and capital ...
(Date:7/25/2014)... 2014 (HealthDay News) -- Although cervical cancers are declining ... to human papillomavirus (HPV) are increasing, a new study ... base of the tongue and tonsils have increased over ... younger than 45, the Canadian researchers report. "The ... younger men and of anal cancer among younger women ...
(Date:7/25/2014)... July 25, 2014 The Europe Cyber ... market in Europe with analysis and forecast of revenue. ... billion in 2014 to $19.07 billion by 2019, at ... Browse through the TOC of the Europe Cyber Security ... analysis provided. It also provides a glimpse of the ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 The American ... new volunteer network “ABTA CommYOUnity™” during its annual patient ... pivotal time for the brain tumor community as we ... patient and caregiver support services and funding brain tumor ... are passionate about brain tumor awareness and getting our ...
(Date:7/25/2014)... July 25, 2014 Today, nearly 700,000 people ... yet, when it comes to pinpointing causes or risk factors, ... don’t know who, we don’t know when, and we don’t ... MNA, president & CEO, American Brain Tumor Association. “It’s frustrating ... Brain Tumor Association funds research to pursue answers to these ...
Breaking Medicine News(10 mins):Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 2Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 3Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 4Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 5Health News:Anal, Throat Cancers on the Rise Among Young Adults, Study Finds 2Health News:Europe Cyber Security Market is Expected to Reach $19 billion in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Cyber Security Market is Expected to Reach $19 billion in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Cyber Security Market is Expected to Reach $19 billion in 2019 - New Report by MicroMarket Monitor 4Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 2Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 3Health News:Brain Tumor Causes and Risk Factors Elude Scientists 2Health News:Brain Tumor Causes and Risk Factors Elude Scientists 3Health News:Brain Tumor Causes and Risk Factors Elude Scientists 4
... is being developed that will create a calendar-like printout ... of Georgia physical therapist and associate dean, who wanted ... ,Multiple prescriptions can be confusing: knowing which pill is ... have special instructions. ,'The idea came ...
... excessive dandruff and it could be treated as an early ... // ,Barry Stevens, founder of the London Trichology Society, ... common among AIDS patients. ,'Seborrhoeic Dermatitis among HIV-positive ... percent among general population,' he said. ,'Though a ...
... Society (WHS) and Blackwell Publishing are excited to announce ... Wounds in a special issue of Wound Repair and ... ,Because of continued interest by the WHS ... Foundation, a proposal was developed to establish guidelines for ...
... this holiday season? It’s one of the biggest fashion trends this ... back, neck and shoulder pain, headaches and possibly even arthritis. // ... headaches and what I usually do is look for their purse ... on the medical staff at Baylor Medical Center at Garland. ...
... a study that affirms the role of partners or ... ,Publishing results in the January issue of Archives of Dermatology, ... for skin examination sessions are bound to take the sessions ... translates to reduced risks of developing the dreaded melanoma or ...
... met his Waterloo twice, the second time proving fatal, at ... from US, Switzerland and Canada have put to rest a ... of the French conqueror. ,The most recent theory, ... of Napoleons’ hair was that the ruler’s death was due ...
Cached Medicine News:Health News:New Software to Help Patients 2Health News:Pair Up-Prevent Melanoma 2Health News:Mighty Conqueror Felled by Stomach Cancer 2
(Date:7/24/2014)... , Deutschland, und MARSEILLE ... , Weltweite Exklusivlizenz ... ermöglicht QIAGEN die Entwicklung von Tests auf ... Blutkrebs  Neuer Test weist Mutationen ... Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf vermuten ...
(Date:7/24/2014)... COLUMBUS, Ohio, July 24, 2014  Mettler-Toledo International Inc. ... results for 2014.  Provided below are the highlights: ... in the quarter compared with the prior year. Reported ... currency. , Net earnings per diluted share as ... second quarter of 2013. Adjusted EPS was $2.57, an ...
(Date:7/24/2014)... 24, 2014 IGI Laboratories, Inc. (NYSE MKT: ... specialty generic pharmaceutical company, today announced it has accepted  ... Directors.  Mr. Finio has accepted a senior level finance ... of his acceptance of his new position, Mr. Finio ... Director for IGI Laboratories, Inc.  The effective date of ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
... Therapeutics (Nasdaq: FOLD ) will release its first quarter 2010 financial results ... The results announcement will be followed by a live conference call and webcast ... , , ... 5 p.m. EDT by dialing 877-303-5859 (U.S./ Canada ) or 678-224-7784 ...
... April 27 The U.S. Food and Drug Administration today approved the ... in certain adults. , , , ... ) , , , ... is intended for patients ages 18 and older whose severe and persistent asthma ...
Cached Medicine Technology:Amicus Therapeutics to Host its First Quarter 2010 Financial Results Conference Call and Webcast on May 6, 2010 2FDA Approves New Device for Adults with Severe and Persistent Asthma 2FDA Approves New Device for Adults with Severe and Persistent Asthma 3
Performa cemented stem....
M2 cemented hip stem....
Porous foundation 480 series....
Cemented foundation 460 series....
Medicine Products: